Table 1.
(A) | |||||||
Polyphenols | Cancer Type | Type of Assay | Reference | ||||
In Vitro Assay | In Vivo Assay | ||||||
Classes | Compounds | Cell-Lines | Concentration * | Model | Effects | ||
Anthocyanins | Colorectal cancer | HT-29 | 400 μg/mL 2 | Mouse model | ↓ tumour size; ↓ inflammation |
[72] | |
Melanoma | Mouse model | Inhibited tumour growth and lung metastasis. | [64] | ||||
Flavanones | Naringin | Oesophageal cancer | YMI | 354 μM 1 | Mouse model | ↓tumour size. | [68] |
Flavones | Hispidulin | Acute myeloid leukaemia | MOLM-13 | 6.4 μM 1 | - | - | [62] |
MV4-11 | 8.2 μM 1 | - | - | [62] | |||
Luteolin | Lung carcinoma | A549 | 25–100 μM 2 | [73] | |||
Acute myeloid leukaemia | MOLM-13 | 4.5 μM 1 | [62] | ||||
MV4-11 | 3.1 μM 1 | [62] | |||||
Tangeretin | Colorectal carcinoma | HCT116 | 12.5 μM 2 | Mouse model | ↓ tumour incidence; ↓ pathological symptoms |
[74] | |
Flavonols | Kaempferol | Breast carcinoma | Mouse model | ↓ Tumour size | [75] | ||
Isoflavones | Alpinumisoflavone | Leukaemia | CEM/ADR5000 | 5.91 μM 1 | [65] | ||
Breast carcinoma | MDA-MB-231-BCRP | 65.65 μM 1 | [65] | ||||
Lignans | Pycnanthulignene | Leukaemia | CEM/ADR5000 | 5.84 μM 1 | [65] | ||
Colon carcinoma | HCT116 | 65.32 μM 1 | [65] | ||||
Phenolic acid | |||||||
Stilbenes | Pterostilbene | Cervical cancer | TC1 | 15.61 μM 1 | Mouse model | ↓ Tumour size; | [76] |
Pancreatic cancer | - | - | Mouse model | Inhibited tumour growth | [77] | ||
Resveratrol | Cervical cancer | TC1 | 34.46 μM 1 | Mouse model | ↓ Tumour size; | [76] | |
Melanoma | B16F10, A375 and B6 | 40 μM 2 | - | - | [63] | ||
Lung cancer metastasis | - | Mouse model | ↓ Angiogenesis; ↑ apoptosis metastatic colonies in the lungs |
[63] | |||
Phenolic extracts from: | |||||||
Cynara cardunculus L. | Oral carcinoma | SCC-25 | 184.81 μg/mL 1 | - | - | [78] | |
Orange peel | Oesophageal cancer | YMI | Mouse model | ↓ Tumour size. | |||
(B) | |||||||
Compounds | Type of Cancer | Cancer Drug | Effect | Reference | |||
Quercetin | Lung cancer | Paclitaxel-resistant cells | Reversal of PTX resistance mitochondrial membrane potential MMP depolarization | [79] | |||
Luteolin | Lung cancer | TRIAL | Positive effect synergetic | [67] | |||
Orange peel extract | Oesophageal cancer | Doxorubicin | Decreased the side effects of chemotherapeutic treatment | [68] |
Concentration *: 1—values expressed as the concentration required for 50% inhibition of cell proliferation (IC50 values), and 2—concentration that inhibits cell proliferation; TRIAL—tumour necrosis factor-related apoptosis-inducing ligand.